MET and non-small cell lung carcinoma: Capmatinib (Tabrecta, 2020) and tepotinib (Tepmetko, 2021) are two MET TKIs approved by the U.S. FDA for the treatment of MET exon 14 skipping mutation‐positive advanced NSCLC.